Roche chops TNBC programs following PhIII flops, further dimming the spotlight on Array drug
One of Roche’s spotlight PhIII cancer drug hopefuls is losing more of its aura.
All but pulling the plug on the ipatasertib program in triple …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
